BioFactura Launches Capitol Biologics – New CDMO Division to Accelerate Biologics Development from Concept to Clinic
Frederick, Maryland, September 3, 2025: BioFactura, Inc., a clinical‑stage biopharmaceutical company specializing in high‑value biosimilars and critical biodefense medical countermeasures, today announced the formation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies. … Continue reading